Phase 2bData readout

IMG-007 (OX40 Antagonist)

Moderate-To-Severe Atopic Dermatitis

IMAImageneBio

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: IMG-007 (OX40 Antagonist)
Development stage: Phase 2b
Event type: Data readout
Indication: Moderate-To-Severe Atopic Dermatitis

Research summary

What is being tracked?

This catalyst tracks a Phase 2b data readout for IMG-007 (OX40 Antagonist) in Moderate-To-Severe Atopic Dermatitis. The expected timing is based on the latest available company guidance and may change.

Development notes

05/07/26:- ADAPTIVE Ph2b progresses under amended protocol. SID presentation May 15, 2026; topline data Q4 2027. 08/05/26:- ADAPTIVE safety committee cleared continuation; extension opened. Topline data expected Q4 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source